Welcome.
Are you a healthcare professional?

This website contains promotional information for Chiesi's respiratory products, and is intended solely for UK healthcare professionals. Please confirm below, or go back to the home page.

UK-RES-2000248 Feb 2020

You are now leaving Chiesi's website

By clicking this link, you will be taken to a website that is not owned or controlled by Chiesi. Chiesi is not responsible for the content provided on that site.

Continue
Go back

UK-RES-2000003 Jan 2020

INTENDED FOR UK HEALTHCARE PROFESSIONALS
earth
We don’t have a single solution to sustainability. We have many. Find out more
Background
Atimos® Formoterol pMDI logo

Protecting patients and the planet

From being one of the first pharmaceutical companies with a chlorofluorocarbon (CFC)-free beclometasone dipropionate (BDP) treatment, to our ambitious investments in future respiratory innovations,1,2 we know action is needed to protect our planet – but not at the expense of the very best care for people with respiratory diseases.
At Chiesi, we believe true ‘sustainability’ can only be achieved with a broad array of projects that protect both patients and the planet. This holistic approach is key – and means we sometimes see things a little differently than other pharmaceutical companies.
We strive to consider every aspect of the long-term future of respiratory care for patients, healthcare professionals (HCPs) and the planet, for example:  
  • Providing a portfolio of pMDI and DPI devices – giving HCPs both prescribing options depending on patient needs
  • Encouraging inhaler prescribing that best suits the needs of the patient, and helping HCPs to involve patients in their treatment decisions
  • Offering educational and training support for HCPs within the NHS to support the implementation of national and local clinical guidelines
  • Investing millions in respiratory treatments with low global warming potential1
  • Supporting inhaler recycling projects across the UK,3 empowering patients to change the way they dispose of inhalers and return them to local pharmacies 
  • Pledging to become carbon neutral by 2035 by offsetting all greenhouse gas emissions generated by Chiesi1 – well ahead of the UK national target of 2050
Our approach to sustainability may surprise you.
BDP: Beclometasone dipropionate; CFC: Chlorofluorocarbon; DPI: Dry powder inhaler; HFA: Hydrofluoroalkane; pMDI: Pressurised metered dose inhalers.
References:

  1. The way we act. Chiesi Sustainability Report 2019. Available at: https://www.chiesi.uk.com/pdf/Chiesi_Sustainability_Report_2019_ENG.pdf. Accessed November 2020.
  2. PR Web. Chiesi Group Launch New Product Into UK £80 Million Asthma Market. July 26 2006. Available at: https://www.prweb.com/releases/2006/07/prweb415789.htm. Accessed November 2020.
  3. NHS Long Term Plan. January 2019. Available at: https://www.longtermplan.nhs.uk/wp-content/uploads/2019/08/nhs-long-term-plan-version-1.2.pdf. Accessed November 2020.

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Chiesi Limited on 0800 0092329 (UK) or PV.UK@Chiesi.com.